Electronic health record prompts to expand diabetes technology use in type 1 diabetes
Tests electronic record prompts to help clinicians prescribe diabetes technology more equitably.
Key facts
- Who runs it
- T1D Exchange, United States
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- Status
- Recruiting
- People taking part
- 1,178 people, planned
- Started
- 13 Aug 2024
- Expected to end
- 30 Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- EMR-based BPA model
- Placebo (EMR-based without BPA model)
- Record updated
- 17 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for non-Hispanic Black and Hispanic people with type 1 diabetes, aged 2 years or older, who get care at the study centers.
- Age
- From 2 years to 95 years.
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes recorded in the medical record for at least 6 months at the start.
- Earlier treatment
- People who already use automated insulin delivery (AID) at the start cannot join.
Main reasons for not taking part
- Evidence of using automated insulin delivery (AID) at the start
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- non-Hispanic Black and Hispanic individuals
Who cannot take part
- PwT1D with evidence of use of AID at baseline
Other criteria
- Age ≥ 2 years with an EMR diagnosis of T1D for at least 6 months at baseline and receiving care at one of six intervention centers or a matched control at another T1DX-QI center
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 95 years old?
Where in United States
- T1D ExchangeBoston, United StatesContact: Osagie Ebekozien, MPH, MDTaking people
About the trial
What the trial wants to find out
The overall goal of the study is to create a standardized, stakeholder-informed system within EMRs, that will enable an equitable and regular prescription and documentation of advanced diabetes technologies. This will reduce racial disparities and generate an understanding of the reasons behind prescription decisions.
Read full original descriptionShow less
The study will highlight the development and implementation an EMR-based Best Practice Advisory (BPA).
The study will answer whether the EMR-based BPA can effectively reduce disparities. Additionally, it will explore why providers may not prescribe advanced diabetes technologies.
Patients will also be surveyed to understand their perspectives on developing the EMR-based BPA.
The 2 groups in the trial
- ADT use following Best Practice Advisory among non- Hispanic Black and Hispanic Patients with T1DTreatment being tested
ADT use following a BPA intervention among non-Hispanic Black and Hispanic PwT1D receiving care at 6 T1DX-QI centers will be assessed. The EMR-based BPA will be designed to recommend ADT prescription to patients not already using some type of ADT using a rule-based algorithm. ADT will include CGM, insulin pumps, and AID systems. We will work with each of the 6 centers to implement the BPA as part of the Epic EMR. The function will generate a BPA if patient is not utilizing a CGM or pump/AID. If the patient is not on a CGM, pump or AID system (if already using CGM and pump), the BPA will suggest discussing and/or prescribing CGM (or pump/AID) to the provider. The provider will answer in the affirmative or say, "not discussed" or "patient declined." If the provider chooses to opt out of prescribing, they will be forced to provide a reason for not prescribing to advance the screen. Providers in each intervention center will be trained on the BPA process prior to implementation.
Treatment: EMR-based BPA model
- ADT use among non- Hispanic Black and Hispanic Patients with T1DPlacebo, for comparison
The arm will comprise of a matched control non-Hispanic Black and Hispanic PwT1D receiving care at a center over a 12-month period. Participants will be matched on the basis of Age categories, biological sex, Insurance status, Area deprivation index, Baseline Technology use, Duration of T1D bins, and Baseline HbA1c.
Treatment: Placebo (EMR-based without BPA model)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Implementing Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
- Plain-language title
- Electronic health record prompts to expand diabetes technology use in type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06931275, who can take part
- Publications
- Record updated
- 17 April 2025